LENSAR (NASDAQ:LNSR) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of LENSAR (NASDAQ:LNSR) from a hold rating to a buy rating in a research note published on Sunday.

Several other equities research analysts have also recently issued reports on the stock. BTIG Research raised their target price on shares of LENSAR from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Lake Street Capital reiterated a “buy” rating and set a $13.00 target price on shares of LENSAR in a research note on Thursday, August 13th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of LENSAR in a report on Friday, August 7th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $11.50.

LENSAR Stock Performance

Shares of NASDAQ:LNSR opened at $8.68 on Friday. The firm has a market cap of $106.68 million, a price-to-earnings ratio of -26.30 and a beta of 0.89. The business has a 50-day simple moving average of $6.16 and a two-hundred day simple moving average of $7.19. LENSAR has a fifty-two week low of $4.95 and a fifty-two week high of $12.96.

LENSAR (NASDAQ:LNSR) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.26. LENSAR had a net margin of 57.57% and a negative return on equity of 529.08%. The firm had revenue of $16.50 million for the quarter, compared to the consensus estimate of $14.65 million.

Institutional Trading of LENSAR

Several large investors have recently added to or reduced their stakes in the business. DCF Advisers LLC bought a new position in LENSAR in the second quarter worth approximately $675,000. Sanctuary Advisors LLC purchased a new position in shares of LENSAR during the 2nd quarter worth $96,000. Groupe la Francaise grew its position in shares of LENSAR by 16.2% during the 1st quarter. Groupe la Francaise now owns 213,537 shares of the company’s stock valued at $1,273,000 after acquiring an additional 29,813 shares during the period. Royal Bank of Canada grew its position in shares of LENSAR by 78.2% during the 1st quarter. Royal Bank of Canada now owns 20,095 shares of the company’s stock valued at $120,000 after acquiring an additional 8,818 shares during the period. Finally, Rangeley Capital LLC increased its stake in shares of LENSAR by 6.8% in the 1st quarter. Rangeley Capital LLC now owns 63,000 shares of the company’s stock worth $375,000 after purchasing an additional 4,000 shares in the last quarter. 40.15% of the stock is currently owned by institutional investors.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.